Zacks Research Predicts Weaker Earnings for HealthEquity

HealthEquity, Inc. (NASDAQ:HQY) – Research analysts at Zacks Research lowered their Q3 2027 earnings per share (EPS) estimates for HealthEquity in a note issued to investors on Tuesday, June 24th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.88 per share for the quarter, down from their previous forecast of $0.91. The consensus estimate for HealthEquity’s current full-year earnings is $2.32 per share.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million during the quarter, compared to analysts’ expectations of $322.25 million. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%. During the same quarter in the prior year, the business earned $0.80 earnings per share.

HQY has been the subject of a number of other research reports. Wall Street Zen upgraded HealthEquity from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. JMP Securities upped their price objective on HealthEquity from $110.00 to $117.00 and gave the company a “market outperform” rating in a research report on Wednesday, June 4th. The Goldman Sachs Group upped their price objective on HealthEquity from $94.00 to $104.00 and gave the company a “neutral” rating in a research report on Wednesday, June 4th. Raymond James Financial raised HealthEquity from an “outperform” rating to a “strong-buy” rating and cut their price target for the company from $120.00 to $115.00 in a report on Tuesday, March 25th. Finally, Bank of America boosted their price target on HealthEquity from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, June 4th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, HealthEquity has an average rating of “Buy” and a consensus target price of $118.09.

HealthEquity Stock Up 0.0%

HealthEquity stock opened at $104.88 on Thursday. The stock has a market cap of $9.07 billion, a PE ratio of 76.55, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.06 and a current ratio of 4.06. HealthEquity has a one year low of $65.01 and a one year high of $116.65. The stock has a fifty day moving average of $98.01 and a 200 day moving average of $98.00.

Hedge Funds Weigh In On HealthEquity

A number of hedge funds have recently made changes to their positions in the business. Pier Capital LLC purchased a new stake in shares of HealthEquity in the fourth quarter worth about $8,024,000. HighTower Advisors LLC lifted its position in shares of HealthEquity by 4.8% in the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company’s stock worth $9,122,000 after buying an additional 4,370 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of HealthEquity by 4.7% in the fourth quarter. Wells Fargo & Company MN now owns 124,940 shares of the company’s stock worth $11,988,000 after buying an additional 5,594 shares in the last quarter. Geneva Capital Management LLC lifted its position in shares of HealthEquity by 24.6% in the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company’s stock worth $100,642,000 after buying an additional 206,894 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of HealthEquity by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company’s stock worth $104,280,000 after buying an additional 25,004 shares in the last quarter. Institutional investors own 99.55% of the company’s stock.

Insider Buying and Selling at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of the company’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the transaction, the director now owns 84,969 shares of the company’s stock, valued at $6,597,842.85. This represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of the company’s stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the transaction, the executive vice president now directly owns 56,655 shares of the company’s stock, valued at approximately $4,433,820.30. This trade represents a 13.55% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 304,581 shares of company stock valued at $33,664,018. Company insiders own 1.50% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.